Luo Xiaodan, Chen Ao, Qin Le, Weinkove Robert, Zhao Rong, Ye Ting, Chen Sihui, Tang Jianli, Liu Jianbo, Huang Jiayu, Shi Boyun, Yuan Danyun, Tan Huo, Qin Dajiang, Tang Zhaoyang, Li Peng, Zheng Runhui
The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
China-New Zealand Joint Laboratory on Biomedicine and Health, Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong- Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Front Immunol. 2024 Dec 9;15:1497736. doi: 10.3389/fimmu.2024.1497736. eCollection 2024.
This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.
本研究通过将自体造血干细胞移植（ASCT）与串联抗CD19/CD22嵌合抗原受体（CAR）T细胞疗法相结合，探索一种针对复发/难治性（R/R）伯基特淋巴瘤（BL）的新型治疗策略。一名20岁难治性BL亚洲男性患者，其淋巴瘤对多种化疗免疫治疗方案均无反应，接受了清髓性ASCT，三天后输注了一种新型第三代CAR T细胞，该细胞工程化构建有CD28和CD3ζ信号域以及TLR2共刺激域。在306天的随访中实现了持续完全缓解，且未出现任何严重并发症。该病例表明，清髓性ASCT与串联抗CD19/CD22 CAR T细胞疗法相结合可能是R/R BL的一种有效治疗方法，值得进一步进行临床验证。
